期刊
MULTIPLE SCLEROSIS JOURNAL
卷 28, 期 3, 页码 480-486出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/13524585211038291
关键词
Clinical trial; neuromyelitis optica (NMO)
资金
- Alexion Pharmaceuticals
Eculizumab monotherapy effectively prevents relapses in AQP4-IgG + NMOSD patients, relieving the burden of chronic immunosuppression.
During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks-5.2 years). At 192 weeks (similar to 4 years), 96% of these patients were free from adjudicated relapses (Kaplan-Meier analysis; 95% confidence interval, 75.7-99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据